STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

NCT07280585 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

420

Enrollment

OTHER

Sponsor class

Conditions

Polycystic Kidney, Autosomal Dominant

Interventions

DRUG: Dapagliflozin 10 mg
DRUG: Matching Placebo

Sponsor

University of Cologne

Collaborators

[object Object]